Abbvie is certainly a great company, but they are in a critical period of time that will test their metal. As you suggest, "wait and see" is probably the most prudent investor step; ...

AbbVie's pair of immunology drugs is expected to help drive growth into the next decade. The company should successfully ...

Pharmaceutical company AbbVie (NYSE:ABBV) reported Q4 CY2024 results , with sales up 5.6% year on year to $15.1 billion. Its non-GAAP profit of $2.16 per share was 4.3% below analysts’ consensus ...

A look at the shareholders of AbbVie Inc. (NYSE:ABBV) can tell us which group is most powerful. We can see that institutions ...

Pharmaceutical company AbbVie (NYSE:ABBV) in Q1 CY2025, with sales up 8.4% year on year to $13.34 billion. Its non-GAAP profit of $2.46 per share was 2.6% above analysts’ consensus estimates. Is ...

AbbVie has strong growth potential in various therapeutic and aesthetic markets, driven by novel drugs and market penetration. The company has raised its full-year earnings guidance and expects ...

Leading healthcare company AbbVie (NYSE: ABBV) appears to be hungry for deals to help it diversify its revenue streams. That's because it will need to become less reliant on Humira, its ...

AbbVie is buying ImmunoGen in a deal valued at about $10.1 billion with the goal of speeding the pharmaceutical’s entry into the market for ovarian cancer treatments. ImmunoGen Inc. developed… ...

NORTH CHICAGO, Ill., Oct. 28, 2020 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced the Phase 3 GEMINI 1 and 2 clinical trials evaluating the efficacy, safety and ...

Pharmaceutical company AbbVie (ABBV-2.35%) has been a double-deal of price growth and dividend income over the past five years. It achieved 129% in total returns in that time, outpacing the S&P 500 .

Pharmaceutical giant AbbVie said Thursday it has agreed to pay more than $10 billion to buy Waltham cancer drug maker ImmunoGen, in the largest acquisition of a Massachusetts company this year.

VUITY is the first and only eye drop to treat presbyopia, or age-related blurry near vision, in adults and is FDA-approved for once-daily administration In the VIRGO trial evaluating twice-daily ...